Hypertrophic cardiomyopathy in MYBPC3 carriers in aging
- PMID: 38406555
- PMCID: PMC10883298
- DOI: 10.20517/jca.2023.29
Hypertrophic cardiomyopathy in MYBPC3 carriers in aging
Abstract
Hypertrophic cardiomyopathy (HCM) is characterized by abnormal thickening of the myocardium, leading to arrhythmias, heart failure, and elevated risk of sudden cardiac death, particularly among the young. This inherited disease is predominantly caused by mutations in sarcomeric genes, among which those in the cardiac myosin binding protein-C3 (MYBPC3) gene are major contributors. HCM associated with MYBPC3 mutations usually presents in the elderly and ranges from asymptomatic to symptomatic forms, affecting numerous cardiac functions and presenting significant health risks with a spectrum of clinical manifestations. Regulation of MYBPC3 expression involves various transcriptional and translational mechanisms, yet the destiny of mutant MYBPC3 mRNA and protein in late-onset HCM remains unclear. Pathogenesis related to MYBPC3 mutations includes nonsense-mediated decay, alternative splicing, and ubiquitin-proteasome system events, leading to allelic imbalance and haploinsufficiency. Aging further exacerbates the severity of HCM in carriers of MYBPC3 mutations. Advancements in high-throughput omics techniques have identified crucial molecular events and regulatory disruptions in cardiomyocytes expressing MYBPC3 variants. This review assesses the pathogenic mechanisms that promote late-onset HCM through the lens of transcriptional, post-transcriptional, and post-translational modulation of MYBPC3, underscoring its significance in HCM across carriers. The review also evaluates the influence of aging on these processes and MYBPC3 levels during HCM pathogenesis in the elderly. While pinpointing targets for novel medical interventions to conserve cardiac function remains challenging, the emergence of personalized omics offers promising avenues for future HCM treatments, particularly for late-onset cases.
Keywords: Age-related HCM; MYBPC3; alternative splicing; chaperone-mediated autophagy; nonsense-mediated decay; ubiquitin-proteosome system.
Conflict of interest statement
Conflict of interest Sadayappan S provides consulting and collaborative research studies to the Leducq Foundation (CUREPLAN), Red Saree Inc., Greater Cincinnati Tamil Sangam, Affinia Therapeutics Inc., and Cosmogene Skincare Private Limited, but such work is unrelated to the content of this article. Dr. Ananthamohan K and Dr. Stelzer JE have no conflicts of interest to disclose.
Figures





Similar articles
-
A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.Circulation. 2019 Feb 5;139(6):799-811. doi: 10.1161/CIRCULATIONAHA.118.034624. Circulation. 2019. PMID: 30586709 Free PMC article.
-
Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.Pflugers Arch. 2019 May;471(5):781-793. doi: 10.1007/s00424-018-2226-9. Epub 2018 Nov 20. Pflugers Arch. 2019. PMID: 30456444 Free PMC article. Review.
-
An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy.Int J Mol Sci. 2023 Jun 22;24(13):10510. doi: 10.3390/ijms241310510. Int J Mol Sci. 2023. PMID: 37445689 Free PMC article. Review.
-
Hypertrophic cardiomyopathy-linked variants of cardiac myosin-binding protein C3 display altered molecular properties and actin interaction.Biochem J. 2018 Dec 14;475(24):3933-3948. doi: 10.1042/BCJ20180685. Biochem J. 2018. PMID: 30446606
-
A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy.ESC Heart Fail. 2023 Aug;10(4):2711-2717. doi: 10.1002/ehf2.14424. Epub 2023 Jun 4. ESC Heart Fail. 2023. PMID: 37271167 Free PMC article.
Cited by
-
Transcriptomic analysis and machine learning modeling identifies novel biomarkers and genetic characteristics of hypertrophic cardiomyopathy.Front Genet. 2025 Jun 17;16:1596049. doi: 10.3389/fgene.2025.1596049. eCollection 2025. Front Genet. 2025. PMID: 40599543 Free PMC article.
-
Generation of Isogenic iPSC Lines for Studying the Effect of the p.N515del (c.1543_1545delAAC) Variant on MYBPC3 Function and Hypertrophic Cardiomyopathy Pathogenesis.Int J Mol Sci. 2024 Nov 30;25(23):12900. doi: 10.3390/ijms252312900. Int J Mol Sci. 2024. PMID: 39684611 Free PMC article.
-
Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies.Egypt Heart J. 2025 Jan 7;77(1):5. doi: 10.1186/s43044-024-00600-4. Egypt Heart J. 2025. PMID: 39776022 Free PMC article. Review.
-
MYBPC3 D389V Variant Induces Hypercontractility in Cardiac Organoids.Cells. 2024 Nov 19;13(22):1913. doi: 10.3390/cells13221913. Cells. 2024. PMID: 39594661 Free PMC article.
References
-
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015;65:1249–54. - PubMed
-
- American College of Cardiology Foundation/American Heart Association Task Force on P, American Association for Thoracic S, American Society of E, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2011;142:e153–203. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous